

**Harvard Medical School  
Curriculum Vitae**

**Date Prepared:** July 1, 2025  
**Name:** Wenxin Xu  
**Office Address:** Dana-Farber Cancer Institute  
450 Brookline Avenue, Dana 909  
Boston, MA 02215  
**Home Address:** 123 Clark Street  
Newton, MA 02458  
**Work Phone:** 617-632-6534  
**Work Email:** Wenxin\_Xu1@dfci.harvard.edu  
**Place of Birth:** Xuyong, Sichuan, China

**Education**

2009	BA (Summa Cum Laude)	Chemical and Physical Biology	Harvard College, Cambridge, MA
2014	MD (Cum Laude)	Medicine	Harvard Medical School (HMS), Boston, MA

**Postdoctoral Training**

6/2014-6/2017	Resident	Internal Medicine	Beth Israel Deaconess Medical Center (BIDMC), Boston, MA
6/2014-6/2020	Clinical Fellow	Medicine	HMS
7/2017-6/2020	Clinical Fellow	Hematology/Oncology	BIDMC

**Faculty Academic Appointments**

7/2020- 11/2023	Instructor	Medicine	HMS
12/2023-	Assistant Professor	Medicine	HMS

**Appointments at Hospitals/Affiliated Institutions**

7/2020-	Associate Physician	Medicine (Medical Oncology)	Brigham and Women's Hospital (BWH), Boston, MA
7/2020-	Physician	Medical Oncology	Dana-Farber Cancer Institute (DFCI), Boston, MA

**Committee Service**

**Local**

2021-2023	Clinical Faculty Council	DFCI
2022-	Data Safety Monitoring Board	DFCI

**National**

2023	Abstract Selection Committee, Kidney Cancer Research Summit Meeting	KidneyCAN
2024	International Kidney Cancer Symposium: North America Oral Abstracts	Kidney Cancer Association
2025	Abstract Selection Committee, AACR Annual Meeting	American Association for Cancer Research

**Professional Societies**

2017-	American Society of Clinical Oncology (ASCO)
2018-	American Association for Cancer Research (AACR)
2019-	European Society for Medical Oncology (ESMO)
2023-	Society for Immunotherapy in Cancer (SITC)
2023-	Member, Renal Cell Carcinoma Immunotherapy Guideline Expert Panel

## **Editorial Activities**

### ***Ad hoc* Reviewer**

*American Journal of Clinical Oncology*

*British Journal of Cancer*

*Clinical Immunology*

*Clinical Therapeutics*

*HPB*

*JCI Insight*

*JCI*

*Journal of Blood Cancer*

*Journal of Clinical Oncology*

*JCO Clinical Cancer Informatics*

*Proceedings of the National Academy of Sciences (PNAS)*

## **Honors and Prizes**

2007	Detur Book Prize	Harvard College
2009	Phi Beta Kappa, Harvard Chapter	Harvard College

## **Report of Funded and Unfunded Projects**

### **Funding Information**

#### **Past**

2019-2021	Kidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma DF/HCC Kidney Cancer Specialized Program of Research Excellence (SPORE), Career Enhancement Award PI The goal of this study was to evaluate KIM-1 using biobanked plasma
-----------	---

samples to differentiate benign versus malignant kidney masses and to evaluate KIM-1 as a prognostic biomarker for adjuvant and advanced RCC.

- 2020-2021  
Clinical Characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma  
ASCO Young Investigator Award, Conquer Cancer Foundation  
PI  
The goal of this project was to evaluate KIM-1 as an RCC biomarker by analyzing banked plasma samples to determine the correlation between KIM-1 and subsequent clinical outcomes in localized and metastatic settings.
- 2020-2022  
Using Unstructured Clinical Data to Annotate and Predict Immune Related Adverse Events  
DF/HCC Kidney Cancer SPORE, Career Enhancement Award  
PI  
The major goals of this project are: Develop machine learning to identify past immune related adverse events (irAEs) in electronic medical records, examine whether models can be trained to predict future irAEs using unstructured clinical data, and to build ensemble models for irAE prediction using multiple clinical data streams.
- 2022-2023  
Adoptive Cytokine-induced Memory-like NK Cell Therapy Alone or in Combination with Avelumab for Immunotherapy-refractory Advanced Renal Cell Carcinoma  
Kidney Cancer Association (KCA), Advanced Discovery Award  
Co-Investigator (PI: Toni Choueiri)  
Aim 1: Evaluate the safety and antitumor efficacy of CIML-NK cell immunotherapy in advanced ccRCC. Aim 2: Investigate the *in vivo* biology (proliferation, trafficking, and antitumor response) of adoptively transferred CIML-NK cells in advanced ccRCC. This is expected to end in October 2023.

## Current

- 2022-2026  
Circulating Biomarkers of Renal Cell Carcinoma  
Department of Defense, KCRP Academy of Kidney Cancer Investigators, Early Career Investigator Award  
PI (\$725,000)  
Aim 1: Evaluate plasma KIM-1 with or without cfMeDIP-seq as a diagnostic aid in patients with renal masses; Aim 2: Validate KIM-1 to predict clinical outcomes in the adjuvant setting; and Aim 3: Assess KIM-1 as a biomarker

for mortality risk and likelihood of response to initial treatment in metastatic RCC.

2024-2027 Mechanisms and Predictors of Adoptive Cytokine-induced Memory-like NK Cell Therapy in Renal Cell Carcinoma  
Department of Defense, Translational Partnership Award  
Co-Investigator (PI: Toni Choueiri and Rizwan Romee)  
Aim 1: Deep phenotypic and transcriptomic characterization of naïve NK cells and adoptively transferred CIML-NK cells in advanced ccRCC. Aim 2: Determine predictive biomarkers for CIML-NK therapy in ccRCC. Status: Recommended for funding; still pending as of 11/9/2023.

### **Unfunded Current Projects**

2021- Pilot Study of Implantable Microdevice for Evaluating Drug Responses *in situ* in Renal Cell Carcinoma (PI) (DFCI 22-492)  
The goal of this phase 1 study is to assess the feasibility and safety of an implantable microdevice for evaluating *in vivo* response to medications in RCC.

### **Report of Local Teaching and Training**

#### **Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)**

2020-	GU Journal Club DFCI	Fellows, faculty, residents, NPs, and PAs One 30-minute session per month
2023	Evaluation and Treatment of Renal Cell Carcinoma DFCI	Oncology fellows 90-minute session
2022	Evaluation and Treatment of Renal Cell Carcinoma DFCI	Oncology fellows 90-minute session
2022	Professional Development Series: Finding a Job BIDMC	3 <sup>rd</sup> year oncology fellows 60-minute session

### **Clinical Supervisory and Training Responsibilities**

2020-	Ambulatory Clinic Preceptor, Medical Oncology DFCI	NPs, PAs 4 half-days per week
2020-	Ambulatory Clinic Preceptor, Medical Oncology DFCI	Medical Oncology fellows 2 half-days per week, 48 weeks per year
2021-	Inpatient Attending, Medical Oncology BWH	Residents 6 hours per day, 7 days per week, 1 week per year
2021-	Inpatient Attending, Medical Oncology BWH	PAs 6 hours per day, 7 days per week, 3 weeks per year

**Laboratory and Other Research Supervisory and Training Responsibilities**

2020-	Supervision (in conjunction with research collaborators) DFCI	Post-doctoral Research Fellows, Research Associate One hour per week per trainee
-------	--	--

**Other Mentored Trainees and Faculty**

- 2020-2021 Andrew Piper-Vallillo, MD / Medical Oncologist, Lahey Hospital and Medical Center, Burlington, MA  
*Career stage:* Clinical fellow // *Mentoring role:* Research co-mentor (Co-mentor: Mary Linton Peters)  
*Accomplishments:* Contributing author in paper published in *Cancer Medicine*.
- 2020-2021 Brian Halbert, MD / Clinical Fellow in Hematology/Oncology, BIDMC  
*Career stage:* Clinical fellow // *Mentoring role:* Research co-mentor (Co-mentor: Rupal Bhatt)  
*Accomplishments:* Contributing author in paper published in *Clinical Cancer Research*.
- 2020-2021 Jon Wischhusen, MD / Clinical Fellow in Hematology/Oncology, BIDMC  
*Career stage:* Clinical fellow // *Mentoring role:* Research co-mentor (Co-mentor: Mary Linton Peters)  
*Accomplishments:* Contributing author in paper published in *Cancer Medicine*.

- 2020-2021 Poorva Bindal, MD / Clinical Fellow in Hematology/Oncology, BIDMC  
*Career stage:* Clinical fellow // *Mentoring role:* Research co-mentor (Co-mentor: Mary Linton Peters)  
*Accomplishments:* Contributing author in paper published in *Cancer Medicine*.
- 2021-2023 Chris Labaki, MD / Resident, Internal Medicine, Beth Israel Deaconess Medical Center (BIDMC), Boston, MA  
*Career stage:* Postdoctoral Associate // *Mentoring role:* Teaching mentor  
*Accomplishments:* Development of teaching skills leading to co-leadership of the DFCI Genitourinary Cancers Journal Club.
- 2022-2024 Renée Maria Saliby / Visiting Scientist, Medical Oncology, DFCI, Research Associate in Medicine, HMS  
*Career stage:* Postdoctoral Associate // *Mentoring role:* Research co-mentor (Co-mentor: Toni Choueiri)  
*Accomplishments:* Investigating the effects of the microbiome on renal cell carcinoma. Development of teaching skills leading to co-leadership of the DFCI Genitourinary Cancers Journal Club.
- 2024- Prateek Khanna / Clinical Fellow in Hematology/Oncology, Dana-Farber Cancer Institute / St. Elizabeth Medical Center  
 (Co-mentor: Srinivas Viswanathan)  
*Accomplishments:* Clinical mentor in genitourinary malignancies. Research mentor in developing a new clinical trial protocol in kidney cancer.
- 2024- Marc Machaalani / Visiting Scientist, Medical Oncology, DFCI, Research Associate in Medicine, HMS  
*Career stage:* Postdoctoral Associate // *Mentoring role:* Research co-mentor (Co-mentor: Toni Choueiri)  
*Accomplishments:* Development of circulating biomarkers in renal cell carcinoma.
- 2024- Clara Steiner / Visiting Scientist, Medical Oncology, DFCI, Research Associate in Medicine, HMS  
*Career stage:* Postdoctoral Associate // *Mentoring role:* Research co-mentor (Co-mentor: Toni Choueiri)  
*Accomplishments:* Implantable microdevice development in renal cell carcinoma. Development of proteomic biomarkers in renal cell carcinoma.
- 2024- Liliana Ascione / Visiting Scientist, Medical Oncology, DFCI, Research Associate in Medicine, HMS  
*Career stage:* Postdoctoral Associate // *Mentoring role:* Research co-mentor

(Co-mentor: Toni Choueiri)

*Accomplishments:* Novel biomarkers in non-clear cell renal cell carcinoma.  
Determinants of response to HIF-2 inhibitors in renal cell carcinoma.

**Formal Teaching of Peers (e.g., CME and other continuing education courses)**

*No presentations below were sponsored by outside entities*

2022	Advanced Disease: First Line Options 21 <sup>st</sup> Biennial Course in Urologic Oncology, HMS	Single presentation Boston, MA (virtual)
2022	Expert Panel: Renal Cell Carcinoma 21 <sup>st</sup> Biennial Course in Urologic Oncology, HMS	Panelist Boston, MA (virtual)
2024	Advanced Disease: First Line Options 22 <sup>nd</sup> Biennial Course in Urologic Oncology, HMS	Single presentation Boston, MA (virtual)
2024	Expert Panel: Renal Cell Carcinoma 21 <sup>nd</sup> Biennial Course in Urologic Oncology, HMS	Panelist Boston, MA (virtual)

**Local Invited Presentations**

*No presentations below were sponsored by outside entities*

2019	Adjuvant Therapy in Renal Cell Carcinoma / Grand Rounds Division of Urology, BIDMC	
2019	Salvage Prostatectomy After Radiation Therapy for Prostate Cancer / Grand Rounds Genitourinary Oncology Program, Division of Medical Oncology, BIDMC	
2020	KIM-1 as a Plasma Biomarker in Renal Cell Carcinoma / Invited lecture Harvard Catalyst Research Day, Harvard Catalyst, Boston, MA (virtual)	
2021	GU-ASCO Update Speaker Series / Invited lecture Kidney Cancer Program, DF/HCC, MA (virtual)	

- 2022, 2023 ASCO GU Update, Renal Cell Carcinoma / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)
- 2022 ASCO Recap, Prostate Cancer / Invited lecture  
Oncoclinicas, São Paulo, Brazil (virtual)
- 2022 ASCO Update, Renal Cell Carcinoma / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)
- 2022 Circulating Biomarkers in Renal Cell Carcinoma / Invited lecture  
Kidney Cancer Program Seminar Series, DF/HCC (virtual)
- 2022 ESMO Update, Renal Cell Carcinoma / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)
- 2023 AACR Renal Cell Carcinoma Update / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)
- 2023 Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma / Invited  
lecture  
Sun Yat-sen University, Guangzhou, China (virtual)
- 2024 Anti-angiogenesis Therapies in Renal Cell Carcinoma / Invited lecture  
Boston Angiogenesis Meeting, The Starr Center
- 2024 ESMO Updates in Genitourinary Oncology / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)
- 2025 ASCO Genitourinary Cancers Symposium Updates / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)
- 2025 AACR Updates in Genitourinary Oncology / Invited lecture  
Lank Center for Genitourinary Oncology, Department of Medical  
Oncology, DFCI (virtual)

**Report of Regional, National and International Invited Teaching and Presentations  
Invited Presentations and Courses**

*No presentations below were sponsored by outside entities*

**Regional**

- 2019 Novel Biomarkers in Renal Cell Carcinoma / Grand Rounds  
Division of Hematology/Oncology, Boston Medical Center (BMC), Boston, MA
- 2019 Novel Biomarkers in Renal Cell Carcinoma / Invited lecture  
Division of Hematology/Oncology, Rhode Island Hospital (RIH) / Brown Medical School, Providence, RI
- 2019 Novel Biomarkers in Renal Cell Carcinoma / Invited lecture  
Division of Hematology/Oncology, Maine Medical Center, Portland, ME

**National**

- 2019 Novel Biomarkers in Renal Cell Carcinoma / Invited lecture  
Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
- 2019 Novel Biomarkers in Renal Cell Carcinoma / Invited lecture  
Division of Medical Oncology, Houston Methodist Cancer Center, Houston, TX
- 2020 KIM-1 as a Circulating Biomarker in Kidney Cancer / Invited lecture  
Eastern Cooperative Oncology Group (ECOG) Young Investigator Symposium (virtual)
- 2022 Adjuvant Therapy in Renal Cell Carcinoma / Invited  
Updates in Renal Cell Carcinoma, The ASCO Post Roundtable (virtual)
- 2022 Biomarkers in Non-Clear Cell RCC / Invited lecture  
Society of Urologic Oncology Annual Meeting, San Diego, CA
- 2022 Circulating Biomarkers in Kidney Cancer / Invited lecture  
International Kidney Cancer Symposium: North America, Austin, TX
- 2022 Current and Emerging Therapies for RCC / Invited lecture  
Precision Medicine Symposium, Jersey City, NJ

- 2022 First-line Therapy in Metastatic Clear Cell Renal Cell Carcinoma / Invited panelist  
Updates in Renal Cell Carcinoma, The ASCO Post Roundtable (virtual)
- 2022 Individualized Prostate Cancer Treatment: Special Considerations for Gay and Bisexual Men / Invited lecture  
Academy for Continued Healthcare Learning, Chicago, IL (virtual)
- 2022 Kinase Inhibitors in RCC / Invited lecture  
Emerging Strategies in the Treatment of Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma), MedNet Online Lecture, MyCME, Paramus, NJ (virtual)
- 2022 Second-line Therapy and Beyond in Clear Cell Renal Cell Carcinoma / Invited panelist  
Updates in Renal Cell Carcinoma, The ASCO Post Roundtable (virtual)
- 2022 Treatment of Non-clear Cell Renal Cell Carcinoma / Invited panelist  
Updates in Renal Cell Carcinoma, The ASCO Post Roundtable (virtual)
- 2022 VHL Targeting in RCCA / Invited lecture  
Improving Renal Cell Carcinoma Patient Outcomes with Multi-targeted TKIs and Immune Checkpoint Inhibitors, MedNet Online Lecture, MyCME, Paramus, NJ (virtual)
- 2022 sKIMing off the Top: KIM-1 as a Biomarker in Renal Cell Carcinoma / Invited lecture  
Department of Urology, Johns Hopkins University (JHU) School of Medicine, Baltimore, MD (virtual)
- 2023 Integrating Novel Therapies & Combination Approaches in Patient-Centered Care for RCC / Invited lecture  
Novel and Emerging Therapies in Renal Cell Carcinoma, Prime Education LLC, Fort Lauderdale, FL
- 2023 KIM 1 and Kidney Cancer: Multiple Setting or an Ideal Setting? / Invited lecture  
Biomarkers in Kidney Cancer Symposium, Boston, MA
- 2023 Optimizing Therapy Selection for Patients With Renal Cell Carcinoma / Invited lecture  
Medscape at ASCO Annual Meeting, Chicago, IL

- 2023 Systemic Therapy for Renal Cell Carcinoma: Immunotherapy vs Immunotherapy + TKIs / Invited lecture  
New York GU: 16th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, Physician's Education Resource, New York, NY
- 2024 Systemic Therapy for Renal Cell Carcinoma / Invited lecture  
New York GU: 17th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, Physician's Education Resource, New York, NY
- 2025 Systemic Therapy for Renal Cell Carcinoma: The Present and Future of Treatment / Invited lecture  
New York GU: 18th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, Physician's Education Resource, New York, NY
- 2025 Essential Biomarkers in RCC / Invited Lecture  
Kidney Cancer Research Summit 2025, Boston, MA
- 2025 From Bench to Bedside: Advancing KIM-1 as a Tool for Clinical Decision-Making / Invited Lecture  
Kidney Cancer Research Summit 2025, Boston, MA

### **National Abstract Oral Presentations**

- 2023 Circulating KIM-1 is a Minimally Invasive Biomarker Correlated with Treatment Response to Nivolumab in Patients with Metastatic Renal Cell Carcinoma / Abstract Oral Presentation  
Kidney Cancer Research Summit 2023, Boston, MA
- 2024 Pilot study of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma / Oral Abstract  
Kidney Cancer Research Summit 2024, Boston, MA
- 2025 RCC Disease Detection and Monitoring in the Localized Setting / Invited Lecture  
Advanced Urologic Cancer Consensus Conference, Miami, FL
- 2025 A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients with Renal Cell Carcinoma or Urothelial Carcinoma / Oral Abstract  
Kidney Cancer Research Summit 2025, Boston, MA

## **International**

- 2022            Second Line Systemic Therapies and Beyond in Metastatic Kidney Cancer, Next Frontiers to Cure Cancer / Invited lecture  
A.C. Carmargo Cancer Center, São Paulo, Brazil (virtual)
- 2024            The Needle in the Haystack: Finding Biomarkers in Kidney Cancer / Invited discussion  
ASCO Annual Meeting, Chicago, IL
- 2025            Evaluation of Circulating Kidney Injury Marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214  
ASCO Genitourinary Cancers Symposium, San Francisco, CA
- 2025            Novel Biomarkers to Predict Recurrence / Invited Lecture  
14<sup>th</sup> Canadian Kidney Cancer Forum, Toronto, Canada
- 2025            The future of anti-HIF and novel targets in RCC / Invited Lecture  
14<sup>th</sup> Canadian Kidney Cancer Forum, Toronto, Canada

## **Report of Clinical Activities and Innovations**

### **Past and Current Licensure and Certification**

- 2017            Certification, Internal Medicine, American Board of Internal Medicine (ABIM)
- 2018            Massachusetts Medical License
- 2020            Certification, Medical Oncology, ABIM

### **Practice Activities**

- |       |                   |                        |                              |
|-------|-------------------|------------------------|------------------------------|
| 2020- | Ambulatory Care   | Medical Oncology, DFCI | 3 half-day sessions per week |
| 2020- | Inpatient Service | Medical Oncology, BWH  | 3 weeks per year             |

### **Clinical Innovations**

I identified a deficiency in the BIDMC medical record where automated interaction checking was being unintentionally bypassed for clinical trial medications. Working with research nursing and pharmacy, I incorporated a new workflow at BIDMC for research nurses where research medications

are entered into the OMR medication list to allow automated interaction checking.  
(2019)

There are currently no blood-based biomarkers for kidney cancer. I am developing plasma KIM-1 as a potential new blood test for kidney cancer detection. This includes past and ongoing research projects to demonstrate the predictive and prognostic value of KIM-1 in different clinical contexts, and also to include KIM-1 measurement as part of ongoing prospective clinical trials.  
(2019-)

### **Report of Education of Patients and Service to the Community**

*No presentations below were sponsored by outside entities*

#### **Activities**

- |            |  |
|------------|--|
| 2021, 2022 | Current Medical Therapies for Kidney Cancer / Invited lecture<br>Kidney Cancer Patient Symposium, DF/HCC |
| 2024       | Which treatment is right for me? / Invited lecture<br>Kidney Cancer Patient Symposium, DF/HCC            |
| 2024       | Role of clinical trials in kidney cancer / Invited lecture<br>Kidney Cancer Patient Symposium, DF/HCC    |

#### **Recognition**

- |      |   |   |
|------|---|---|
| 2015 | Delayed BP-Treatment Intensification<br>Linked with CV Events, Mortality<br>(Article) | Medscape:<br><a href="https://www.medscape.com/viewarticle/839323">https://www.medscape.com/viewarticle/839323</a>  |
| 2015 | Pinpointing danger in hypertension<br>(Article)                                       | Harvard Gazette:<br><a href="https://news.harvard.edu/gazette/story/2015/02/pinpointing-danger-in-hypertension/">https://news.harvard.edu/gazette/story/2015/02/pinpointing-danger-in-hypertension/</a>   |
| 2021 | Assessing Population Diversity in<br>Phase III Trials of Cancer Drugs<br>(Interview)  | Oncology Tube:<br><a href="https://oncologytube.com/video/40092/vincent-xu-md-vincentwenxinxu-danafarber-solidtumors-cancer-research-assessing-population-diversity-in-phase-iii-trials-of-cancer-drugs---in-solid-">https://oncologytube.com/video/40092/vincent-xu-md-vincentwenxinxu-danafarber-solidtumors-cancer-research-assessing-population-diversity-in-phase-iii-trials-of-cancer-drugs---in-solid-</a> |

		tumors?channelName=cancernewsupdate #gsc.tab=0
2022	Exploring Adjuvant Therapies in Renal Cell Carcinoma (Interview)	Targeted Oncology: <a href="https://www.targetedonc.com/view/exploring-adjuvant-therapies-in-renal-cell-carcinoma">https://www.targetedonc.com/view/exploring-adjuvant-therapies-in-renal-cell-carcinoma</a>
2022	Trying Not One, But a Three-Drug Combination to Help T Cells Fight Cancer	(Interview) STAT News: <a href="https://www.statnews.com/2022/04/13/in-mice-scientists-try-an-aggressive-combination-therapy-to-treat-ovarian-cancer/">https://www.statnews.com/2022/04/13/in-mice-scientists-try-an-aggressive-combination-therapy-to-treat-ovarian-cancer/</a>
2023	Navigating Systemic Therapy for RCC: Balancing Risk Status and Response	(Interview) <a href="https://www.onclive.com/view/navigating-systemic-therapy-for-rcc-balancing-risk-status-and-response">https://www.onclive.com/view/navigating-systemic-therapy-for-rcc-balancing-risk-status-and-response</a>

### **Report of Scholarship**

ORCID: 0000-0002-8450-2037

\* Co-author, \*\* Mentee

### **Peer-Reviewed publications in print or other media**

#### **Research Investigations**

1. Stevens JB, Liu G, Bremer SW, Ye KJ, **Xu W**, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. Mitotic cell death by chromosome fragmentation. *Cancer Res.* 2007;67(16):7686-94. PMID: 17699772.
2. Brown KM, Costanzo MS, **Xu W**, Roy S, Lozovsky ER, Hartl DL. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. *Mol Biol Evol.* 2010;27(12):2682-90. PMID: 20576759; PMCID: PMC2981517.
3. **Xu W**, Shubina M, Goldberg SI, Turchin A. Body mass index and all-cause mortality in patients with hypertension. *Obesity (Silver Spring).* 2015;23(8):1712-20. PMID: 26179058.
4. **Xu W**, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification and time to follow-up in treatment of hypertension: population-based retrospective cohort study. *BMJ.* 2015 Feb 5;350:h158. PMID: 25655523; PMCID: PMC4353282.

Comment in: Mant J, McManus RJ. Initiation and follow-up of treatment for high blood pressure. *BMJ*. 2015 Feb 5;350:h167. doi: 10.1136/bmj.h167. PMID: 25654977.

Comment in: Vonend O. Blutdruck-Grenzwerte: Zeitnahe Therapie-Anpassung bei erhöhten Werten entscheidend [Elevated blood pressure values - rapid therapy adjustment is crucial]. *Dtsch Med Wochenschr*. 2015 Apr;140(8):554. German. doi: 10.1055/s-0041-101225. Epub 2015 Apr 16. PMID: 25945902.

5. **Xu W**, Puligandla M, Manola J, Bullock A, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS. Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma. *Clin Cancer Res*. 2019;25(20):6098-106. PMID: 31471309; PMCID: PMC7057142.
6. Varkaris A\*, **Xu W\***, Davis RB, Healy B, McDermott DF. Combining immune checkpoint and VEGFR inhibition in favorable-risk and elderly patients with metastatic renal cell carcinoma. *Clin Genitourin Cancer*. 2020 Jun;18(3):179-184.e3. PMID: 32144046. PMCID: PMC7875559.
7. Kehl KL\*, **Xu W\***, Lepisto E, Elmarakeby H, Hassett MJ, Van Allen EM, Johnson BE, Schrag D. Natural language processing to ascertain cancer outcomes from medical oncologist notes. *JCO Clin Cancer Inform*. 2020 Aug;4:680-690. PMID: 32755459; PMCID: PMC7469582.
8. **Xu W**, Piper-Vallillo AJ, Bindal P, Wischhusen J, Patel JM, Costa DB, Peters MLB. Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. *Cancer Med*. 2021 Mar;10(5):1545-9. PMID: 33560590; PMCID: PMC7940218.
9. Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, **Xu W**, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. *Cancer Cell*. 2021 May 10;39(5):632-648.e8. PMID: 33711273; PMCID: PMC8138872.

Comment in: Koh MY, Sayegh N, Agarwal N. Seeing the forest for the trees—single-cell atlases link CD8<sup>+</sup> T cells and macrophages to disease progression and treatment response in kidney cancer. *Cancer Cell*. 2021 May 10;39(5):594-596. doi: 10.1016/j.ccell.2021.03.008. PMID: 33861995.

Comment in: Tregunna R. Immune dysfunction and reprogramming in RCC. *Nat*

Rev Urol. 2021 Jun;18(6):321. doi: 10.1038/s41585-021-00471-3. PMID: 33953372.

10. **Xu W**, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, Dutcher JP, DiPaola RS, Sabbisetti V, Bhatt RS. Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: a trial of the ECOG-ACRIN research group (E2805). *Clin Cancer Res.* 2021 June 15;27(12):3397-403. PMID: 33832947; PMCID: PMC8287837.
11. Yekedüz E, Trapani D, **Xu W**, de Vries EGE, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. *Int J Cancer.* 2021 Oct 01;149(7):1455-62. PMID: 34124786.
12. Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, **Xu W**, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S, McKay RR. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. *JAMA Netw Open.* 2021 Nov 01;4(11):e2134330. PMID: 34767021; PMCID: PMC8590166. Erratum in: Omitted Group Name, Author, Nonauthor Collaborators, Disclosure, and Grant/Support Information. *JAMA Netw Open.* 2021 Dec 1;4(12):e2145075. doi: 10.1001/jamanetworkopen.2021.45075. PMID: 34962566; PMCID: PMC8715345.
13. Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, **Xu W**, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. *JAMA Oncol.* 2021 Dec 01;7(12):1815-23. PMID: 34673916; PMCID: PMC8532040. Erratum in: Error in Table 1. *JAMA Oncol.* 2021 Dec 1;7(12):1904. doi: 10.1001/jamaoncol.2021.6888. PMID: 34913956; PMCID: PMC8678681.
14. Kehl KL, **Xu W**, Gusev A, Bakouny Z, Choueiri TK, Riaz IB, Elmarakeby H, Van Allen EM, Schrag D. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. *Nat Commun.* 2021 Dec 15;12(1):7304. PMID: 34911934; PMCID: PMC8674229.
15. Riaz IB, Riaz Sipra QUA, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, **Xu W**, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH.

Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: a living interactive systematic review and network meta-analysis. *Crit Rev Oncol Hematol.* 2022 May 07;103706. PMID: 35537621. (Peer-reviewed meta-analysis).

16. Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, **Xu W**, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, Choueiri TK, Schrag D, Carrot-Zhang J, Gusev A. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. *Cancer Cell.* 2022 Oct 10;40(10):1161-1172.e5. PMID: 36179682; PMCID: PMC9559771; doi: 10.1016/j.ccell.2022.08.022.
17. Groha S, Alaiwi SA, **Xu W**, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med.* 2022 Dec;28(12):2584-2591. PMID: 36526723
18. Saliby RM, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane MH, Madsen KN, Ficial M, Hirsch L, Wei XX, Steinarter JA, Harshman LC, Vaishampayan UN, Severgnini M, McDermott DF, Lee GM, **Xu W**, Van Allen EM, McGregor BA, Signoretti S, Choueiri TK, McKay RR, Braun DA. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. *Cancer Immunol Res.* 2023 Aug 3;11(8):1114-1124. PMID: 37279009
19. Gupta S, Glezerman IG, Hirsch JS, Chen KL, Devaraj N, Wells SL, Seitter RH, Kaunfer SA, Jose AM, Rao SP, Ortega JL, Green-Lingren O, Hayden R, Bendapudi PK, Chute DF, Sise ME, Jhaveri KD, Page VD, Abramson MH, Motwani SS, **Xu W**, Sehgal K, Reynolds KL, Bansal A, Abudayyeh A, Leaf DEDerivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. *BMJ.* 2024 03 27; 384:e077169. PMID: 38538012
20. **Xu W**, Gu B, Lotter WE, Kehl KL. Extraction and Imputation of Eastern Cooperative Oncology Group Performance Status From Unstructured Oncology Notes Using Language Models. *JCO Clin Cancer Inform.* 2024 May; 8:e2300269. PMID: 38810206.
21. **Xu W**, Gaborieau V, Niman SM, Mukeria A, Liu X, Maremanda KP, Takakura A, Zaridze D, Freedman ML, Xie W, McDermott DF, Choueiri TK, Catalano PJ, Sabbisetti V, Bonventre JV, Pierorazio PM, Singla N, Brennan P, Bhatt RS Plasma Kidney Injury

Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes. *J Clin Oncol*. 2024 May 03; JCO2300699. PMID: 38701382

22. Basaria S, Taplin ME, McDonnell M, Simonson DC, Lin AP, Dufour AB, Habtemariam D, Nguyen PL, Ravi P, Kibel AS, Sweeney CJ, D'Amico AV, Roberts DA, **Xu W**, Wei XX, Sunkara R, Choudhury AD, Mantia C, Beltran H, Pomerantz M, Berchuck JE, Martin NE, Leeman JE, Mouw KW, Kilbridge KE, Bearup R, Kackley H, Kafel H, Huang G, Reid KF, Storer T, Braga-Basaria M, Trivison TG. Insulin resistance during androgen deprivation therapy in men with prostate cancer. *Cancer*. 2024 Nov 01; 130(21):3671-3685. PMID: 38881266; PMCID: PMC11464184.
23. Kehl KL, Jee J, Pichotta K, Paul MA, Trukhanov P, Fong C, Waters M, Bakouny Z, **Xu W**, Choueiri TK, Nichols C, Schrag D, Schultz N. Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research. *Nat Commun*. 2024 Nov 12; 15(1):9787. PMID: 39532885; PMCID: PMC11557593.
24. **Xu W**, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler NR, Labaki C, Saliby RM, Dinh K, Horst JT, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee GM, Hurwitz M, McGregor BA, Hirsch MS, Shukla SA, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. *ESMO Open*. 2025 Jan 14; 10(2):104105. PMID: 39813824.

### **Other peer-reviewed publications**

1. **Xu W**, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. *Nat Rev Urol*. 2020 Mar;17(3):137-50. PMID: 32020040

### **Scholarship without named authorship**

1. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. Clinical impact of COVID-19 on patients with cancer (CCC19\*): a

cohort study. *Lancet*. 2020 Jun 20; 395(10241):1907-18. PMID: 32473681; PMCID: PMC7255743; doi: 10.1016/S0140-6736(20)31187-9. (\*member of the investigative team cited in the appendix of the manuscript)

2. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM; COVID-19 and Cancer Consortium. Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19. *JAMA Oncol*. 2023 Jan 1;9(1):128-134. PMID: 36326731; PMCID: PMC9634600 (\*member of the COVID-19 and Cancer Consortium)
3. Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamara S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshov DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, Rosovsky RP; COVID-19 and Cancer Consortium. Systemic anticancer therapy and thromboembolic outcomes in hospitalized patients with cancer and COVID-19. *JAMA Oncol*. 2023 Oct 1;9(10):1390-1400. PMID: 37589970; PMCID: PMC10436185 (\*member of COVID-19 and Cancer Consortium)

### **Non-peer reviewed scientific or medical publications/materials in print or other media**

#### **Reviews, chapters, monographs and editorials**

1. **Xu W**, Bublely GJ. Repurposed drugs for prostate cancer. *Cancer J*. 2019;25(2):121-6. PMID: 30896534
2. Ravi P, **Xu W**, Mantia C, McGregor B, Schmidt AL. Chapter 7: Genitourinary Malignancies. In: Acharya UH, Dhawale T, eds.. *Oncology Rapid Review*: Wolters Kluwer, 1<sup>st</sup> ed. Philadelphia, PA, 2021, 7-1-7-64.

3. **Xu W**, Choueiri TK. First-line therapy for metastatic clear cell renal cell carcinoma: how to choose between different combinations. ASCO Daily News. 2022. <https://dailynews.ascopubs.org/di/10.1200/AND.22.200809/full/>
4. Saad E, Saliby RM, Labaki C, **Xu W**, Viswanathan SR, Braun DA, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. *Hematol Oncol Clin North Am.* 2023 Jun 28;S0889-8588(23)00078-3. [Online ahead of print.] PMID: 37391289
5. Saliby RM, Saad E, Labaki C, **Xu W**, Braun DA, Viswanathan SR, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. *Hematol Oncol Clin North Am.* 2023 Jun 27;S0889-8588(23)00077-1. [Online ahead of print.] PMID: 37385938
6. Serzan MT, **Xu W**, Berg SA. First-line treatment for intermediate and poor risk advanced or metastatic clear cell renal cell carcinoma. *Hematol Oncol Clin North Am.* 2023 Oct;37(5):951-964. PMID: 37258355

### **Local / Unpublished Clinical Guidelines and Reports**

1. **Xu W**. Imaging characteristics of hepatocellular carcinoma.

### **Thesis**

1. **Xu W**. Optimal Systolic Blood Pressure Target, Time-to-Intensification and Time-to-Follow-up in the Treatment of Hypertension [dissertation]. Harvard Medical School, Boston, MA; 2014.

### **Abstracts, Poster Presentations, and Exhibits Presented at Professional Meetings**

1. **Xu W**, Gusev A, Groha S, Rahma O, Choueiri TK, Kehl KL. Automated Ascertainment of Immune Related Adverse Events Using Machine Learning. 2021 ASCO Annual Meeting , Alexandria, VA (virtual)
2. **Xu W**, Mukeria A, Niman SM, Gaborieau V, Maremanda KP, Zaridze D, Singla N, Freedman ML, McDermott DF, Choueiri TK, Catalano PJ, Sabbisetti V, Brennan P, Bhatt RS. Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma. 2022 ESMO Congress, Paris, France

3. Ikram W, Naqvi SAA, Fatima E, Siddiqi R, Islam M, Asghar N, Khakwani KZR, Khan AM, **Xu W**, Hussain SA, Sonpavde GP, Bryce AH, Riaz IB, Singh P. A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer. 2022 ASCO Genitourinary Cancers Symposium, San Francisco, CA (virtual)
4. Vemula SV\*, **Xu W\***, Wang Y, Liu X, Ruiz de Somocurcio J, McDermott DF, Li J, Bhatt R, Lee CW, Simsek B, Gupta S, Motzer R. High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma. 2024 AACR annual meeting, San Diego, CA
5. Vemula SV\*, **Xu W\***, Verma A, Safta W, Tang C, Chhibber A, Paulucci D, Lee G, Lee CW, Liu X, Chowbene D, Perrot N, Russo P, Bex A, Grunwald V, Choueiri TK, Gupta S, McDermott DF, Bhatt R, Motzer R. Integrative biomarkers analysis from the phase 3 CheckMate 914 trial of nivolumab plus ipilimumab or nivolumab versus placebo for adjuvant clear cell renal cell carcinoma (ccRCC). SITC Annual Meeting, Houston, TX
6. Steiner C, Saad E, Saliby RM, Eid M, Semaan K, Machaalani M, Yekeduz E, Horst J, Lee J, Phillips N, Trowbridge R, Pirovano M, Saldanha Neves Horta Lima C, Gupta S, Lee GS, Elon Y, Dicker A, Bonventre JV, Choueiri TK, **Xu W**. Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA
7. Machaalani M, Saliby RM, Zhong C, Saad E, Steiner C, Liu X, Cai T, Sun M, Lee GS, Xie W, McDermott DF, Choueiri TK, **Xu W**. KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA

## **Narrative Report**

I am a Physician in Medical Oncology at DFCI, an Associate Physician in Medical Oncology at BWH, and an Assistant Professor of Medicine at HMS. My Area of Excellence is Clinical Expertise and Innovation, with a Significant Supporting Activity of Investigation.

I am a medical oncologist who specializes in the care of genitourinary cancers, and my work includes leading early phase clinical trials in kidney cancer. I am developing a clinical investigator focus on novel immunotherapies in kidney cancer, and I am leading several current and upcoming clinical trials including both industry and investigator-initiated trials. In doing so, I work closely with the Immune Effector Cell Therapy program at DFCI. My clinical activities include both ambulatory and inpatient practice. My practice is closely integrated with clinical research and I regularly work with colleagues from other institutions to coordinate patient care and manage consultation requests. I also see patients on the inpatient Medical Oncology service and supervise trainees and PAs in both settings.

SSA - Investigation: I spend significant effort on investigation with a focus on clinical biomarkers. I have led several studies investigating the role of Kidney Injury Molecule-1 (KIM-1) as a renal cell carcinoma biomarker in pre-diagnostic, adjuvant and metastatic settings. This biomarker work was supported by an ASCO/Conquer Cancer Foundation Young Investigator Award, a Career Enhancement Award from the DF/HCC Kidney Cancer SPORE, and currently a DOD Academy of Kidney Cancer Investigators Award. This biomarker has gained increasing acceptance as the first minimally invasive blood test for kidney cancer, and plans are ongoing for prospective validation in clinical trials.

I am principal investigator of several ongoing trials, including two investigator sponsored trials: a new natural killer cell therapy in kidney and bladder cancer (NCT06318871) and an implantable drug testing microdevice in kidney cancer (NCT05700461), as well as other industry sponsored trials. I serve as an ad-hoc peer reviewer for over 10 medical journals and on the abstract committee for the national Kidney Cancer Research Summit and the American Association for Cancer Research, as well as the SITC Renal Cell Carcinoma Guideline Expert Panel as well as grant review committees, reflecting my active participation in the research community.

In my Assistant Professor role, I supervise and teach medical students, residents and fellows, and I lead the monthly genitourinary cancers journal club. Through these activities I aim to develop national and international expertise and improve the standard of care for patients with genitourinary malignancies.